A Beacon of Light on Your Cancer Care Journey


Current Trials

ECHO Open to Acrrual Clinical Trials
Updated: 6/24/20

Bladder / Urothelial

Muscle Invasive

Alliance A031701
A Phase II study of Dose-Dense Gemcitabine plus Cisplatin (DDGC) in patients with Muscle-Invasive Bladder Cancer with Bladder preservation for those patients whose tumors harbor deleterious DNA Damage Response (DDR) Gene alterations

SGTN22E-003 / EV-302
An open-label, randomized, controlled phase 3 study of Enfortumab Vedotin in combination with Pembrolizumab with or without chemotherapy, versus chemotherapy alone in previously untreated locally advanced or metastatic urothelial cancer.

Breast Cancer

CLEE011O12301C (TRIO033 – NATALEE)

A Phase III, multicenter, randomized, open-label trial to evaluate efficacy and safety of Ribociclib with endocrine therapy as an adjuvant treatment in patients with hormone receptor-positive, HER2-negative, early breast cancer (New Adjuvant Trial with Ribociclib [LEE011]: NATALEE)


A phase 3, multicenter, randomized, open-label, active-controlled trial of DS-8201A, an anti-her2-antibody drug conjugate (ADC), versus treatment of physician’s choice for HER2 low, unresectable and/or metastatic breast cancer subjects



NRG-GI004 / SWOG-S1610
Colorectal Cancer Metastatic dMMR Immuno-Therapy (COMMIT) Study: A Randomized Phase III Study of mFOLFOX6 / Bevacizumab Combination Chemotherapy with or without Atezolizumab or Atezolizumab Monotherapy in the First-Line Treatment of Patients with Deficient DNA Mismatch Repair (dMMR) Metastatic Colorectal Cancer


A Phase II, Open-Label Study of Encorafenib + Binimetinib in Patients with BRAFv600E-Mutant Non-Small Cell Lung Cancer

Alchemist Trials Adjuvant Trials for completely resected patients EGFR or ALK positive

Adjuvant Lung Cancer enrichment marker identification and sequencing trial (Alchemist)

Randomized double blind Placebo controlled study of Erlotinib or Placebo in patients with completely resected Epidermal growth factor receptor (EGFR) mutant non-small cell lung cancer (NSCLC)
A phase III double-blind trial for surgically resected early stage Non-Small Cell Lung cancer: Crizotinib versus Placebo for patients with tumors harboring the Anaplastic Lymphoma Kinase (ALK) fusion protein
First Line Metastatic

A Phase II, Multicenter, Randomized, Open-Label, Controlled Study of M7824 (bifunctional fusion protein PDL-1 antibody + TGFβ neutralizing trap) versus Pembrolizumab as a First-line treatment in Patients with PD-L1 Expressing Advanced Non-Small Cell Lung Cancer

A Randomized Phase 3 Multicenter Open-Label Study to compare the efficacy of TAK-788 as first-line treatment versus Platinum-Based Chemotherapy in Patients with Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations

Second Line Metastatic: 

Mirati MRT516-005
A Randomized Phase 3 Study of Sitravatinib in Combination with Nivolumab versus Docetaxel in Patients with Advanced Non-Squamous Non-Small Cell Lung Cancer with Disease Progression on or after Platinum-Based Chemotherapy in Combination with Checkpoint Inhibitor Therapy


Randomized Phase III Trial of Dabrafenib + Trametinib Followed by Ipilimumab + Nivolumab at Progression vs. Ipilimumab + Nivolumab Followed by Dabrafenib + Trametinib at Progression in Patients with Advanced BRAFV600 Mutant Melanoma

Prostate Cancer

LAE201INT2101  – *****On Hold****
A Phase I/II Dose-Escalation and Efficacy Study of LAE001/Prednisone plus Afuresertib in Patients with Metastatic Castration-Resistant Prostate Cancer Following Standard of Care Treatment

A Phase II-III trial of Adjuvant Radiotherapy and Androgen Deprivation Following Radical Prostatectomy with or without Adjuvant Docetaxel

Rectal Cancer


NRG-GI002 ***Temporarily closed to Accrual***

A Phase II Clinical Trial Platform of Sensitization Utilizing Total Neoadjuvant Therapy (TNT) in Rectal Cancer

N1048 / RTOG 1271
A Phase II/III trial of Neoadjuvant FOLFOX, with Selective use of Combined Modality Chemoradiation versus Preoperative Combined Modality Chemoradiation for Locally Advanced Rectal Cancer Patients Undergoing Low Anterior Resection with Total Mesorectal Excision

Renal Cell

A Phase III Randomized Study Comparing Perioperative Nivolumab vs. Observation in Patients with Localized Renal Cell Carcinoma Undergoing Nephrectomy (PROSPER RCC)

Solid Tumors

Open-Label Phase 2 Study of Ladiratuzumab Vedotin (LV) for Unresectable Locally Advanced or Metastatic Solid Tumors


Lung Screening

International Early Lung Cancer Action Program: Enrollment and Screening Protocol

Supportive Care

Amgen Protocol 20170758 Neulasta Onpro *****On Hold****
A Prospective Observational Study to Estimate the Incidence of Febrile Neutropenia (FN) Among Subjects with Non-Myeloid Malignancies at High Risk for FN and Receiving Neulasta (Pegfilgrastim) Onpro kit or other Physician Choice Options for Prophylaxis of FN

CADEX-0001 – ***On Hold***
Development and Validation of a Multiplex qPCR Short Fragment Cell Free DNA Assay as a Potential Biomarker for Predicting Early Non-response to Therapy in Metastatic Cancer

Ready 1 / CUSA-081-HEM-01 /YYA36723
Phase 3, Randomized, Double-Hem-Blind, Active and Placebo Controlled Study on the use of CUSA-081 for Dysfunctional Central Venous Access Devices (CVADs)

Blood Sample Collection to Evaluate Biomarkers in Subjects with Untreated Solid Tumors

Seer – 020102 (SeerPro)
A Prospective Blood Sample Collection Study to Evaluate a Panel of Protein-based Biomarkers

For more information on clinical trials, please contact research@echoassociates.org.